Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vertex Pharmaceuticals
  6. News
  7. Summary
    VRTX   US92532F1003

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment for Cystic Fibrosis in Children

01/11/2022 | 03:50am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
VERTEX PHARMACEUTICALS 0.60% 270.28 Delayed Quote.22.26%
VERTEX, INC. 5.34% 11.2395 Delayed Quote.-32.77%
All news about VERTEX PHARMACEUTICALS
05/23Top Midday Gainers
MT
05/23Catalyst Biosciences Stock Surges After Vertex Pharmaceuticals Buys Catalyst's Compleme..
MT
05/23Catalyst Biosciences Shares Soar After Complement Portfolio Sale
DJ
05/23VERTEX PHARMACEUTICALS INC / MA : Other Events (form 8-K)
AQ
05/23Catalyst Biosciences Sells Complement Portfolio for $60 Million
AQ
05/23SVB Securities Initiates Vertex Pharmaceuticals at Market Perform With $265 Price Targe..
MT
05/23VERTEX PHARMACEUTICALS INCORPORATED : VRTX) acquired Complement Portfolio of Catalyst Bio..
CI
05/19Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
05/18VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (for..
AQ
05/18Suketu Upadhyay Elected to Vertex Board of Directors
BU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2022 8 599 M - -
Net income 2022 3 253 M - -
Net cash 2022 10 823 M - -
P/E ratio 2022 21,2x
Yield 2022 -
Capitalization 68 665 M 68 665 M -
EV / Sales 2022 6,73x
EV / Sales 2023 5,83x
Nbr of Employees 3 900
Free-Float 99,6%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 268,48 $
Average target price 292,59 $
Spread / Average Target 8,98%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS22.26%68 665
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546
GENMAB A/S-19.24%20 071